Type
. Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy. Leprosy review [Internet]. 2006;77(1):25-33. Available from: https://leprosyreview.org/article/77/1/02-5033
Type
. The mouse foot-pad technique for cultivation of Mycobacterium leprae. Leprosy review [Internet]. 2006;77(1):5-24. Available from: https://leprosyreview.org/article/77/1/00-5024
Type
. The mouse footpad model. Leprosy review [Internet]. 2006;77(1):3-4. Available from: https://leprosyreview.org/article/77/1/00-3004
Type
. Final push of leprosy: it is prudent to pause before declaration!. Indian journal of dermatology, venereology and leprology [Internet]. 2006;72(2):151-3; author reply 153. Available from: http://www.ijdvl.com/text.asp?2006/72/2/151/25646
Type
. Incidence of ocular complications in patients with multibacillary leprosy after completion of a 2 year course of multidrug therapy. The British journal of ophthalmology [Internet]. 2006;90(8):949-54. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1857220/pdf/949.pdf
Type
. DC-SIGN interacts with Mycobacterium leprae but sequence variation in this lectin is not associated with leprosy in the Pakistani population. Human immunology. 2006;67(1-2):102-7.
Type
. Impaired maturation and function of dendritic cells by mycobacteria through IL-1beta. European journal of immunology. 2006;36(6):1443-52.
Type
. A Thai patient with generalised inflammatory skin disease 18 years after migration to Europe. Lancet (London, England). 2006;367(9520):1458.
Type
. WHO regional strategy for sustaining leprosy services and further reducing the burden of leprosy, 2006-2010. Indian journal of leprosy. 2006;78(1):33-47.
Type
. WHO global strategy for further reducing the leprosy burden and sustaining leprosy control activities (Plan period: 2006-2010). Indian journal of leprosy. 2006;78(1):7-31.